Pharmacokinetics of Cefaclor in Patients with End Stage Renal Disease and During Hemodialysis
- 1 September 1978
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 14 (3) , 281-283
- https://doi.org/10.1128/aac.14.3.281
Abstract
A single 1.0-g dose of cefaclor administered to patients with stable end stage renal disease whose creatinine clearances were <5 ml/min produced a mean peak serum concentration of 48.3 ± 19.8 μg/ml. The half-life was 2.3 ± 0.3 h. Hemodialysis shortened the half-life of a similar dose to 1.6 ± 0.3 h. Approximately one-third (340 mg) of the administered drug was recovered in the dialysate. Multiple doses of 500 mg every 6 h between hemodialysis sessions produced effective serum concentrations and no bioassay evidence of drug accumulation.This publication has 8 references indexed in Scilit:
- Stability and Blood Level Determinations of Cefaclor, a New Oral Cephalosporin AntibioticAntimicrobial Agents and Chemotherapy, 1978
- In Vitro Studies with Cefaclor, a New Oral CephalosporinAntimicrobial Agents and Chemotherapy, 1977
- In Vitro Activity of Cefaclor, a New Orally Administered Cephalosporin AntibioticAntimicrobial Agents and Chemotherapy, 1977
- Comparison of In Vitro Activity of Cephalexin, Cephradine, and CefaclorAntimicrobial Agents and Chemotherapy, 1977
- Cephalexin in Patients with Renal DiseaseNew England Journal of Medicine, 1970
- Oral Cephalexin and Ampicillin: Antimicrobial Activity, Recovery in Urine, and Persistence in Blood of Uremic PatientsAnnals of Internal Medicine, 1970
- Cephalexin Therapy as Related to Renal FunctionThe Lancet Healthy Longevity, 1970